Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 7Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Malignant Plasma Cell Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Hematologic Diseases 1Corneal Diseases 1Burkitt Lymphoma 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 6fludarabine 5Rituximab 4obinutuzumab 3tafasitamab 2relmacabtagene autoleucel 2pirtobrutinib 2zanubrutinib 1venetoclax 1tisagenlecleucel 1resiniferatoxin 1pomalidomide 1polatuzumab vedotin 1glofitamab 1Vincristine 1Tretinoin 1Surveys and Questionnaires 1Specimen Handling 1Radiotherapy 1Prednisolone 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Immunotherapy, Adoptive 1Immune Checkpoint Inhibitors 1Doxorubicin 1Dexamethasone 1Blood Specimen Collection 1Bendamustine Hydrochloride 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, B-Cell × pomalidomide × Clear all
NCT07532525 2026-04-16

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

University of Michigan Rogel Cancer Center

Phase 1 Not yet recruiting
12 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡